ArticleNutrition journal2025
Impact of muscle mass on mortality in patients with rheumatoid arthritis: insights from NHANES 1999-2018.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMuscle loss is linked to multiple adverse outcomes, but its impact on rheumatoid arthritis (RA) prognosis is unclear. This study aimed to examine the association between muscle mass and mortality in RA patients.
methodsRA patients from the NHANES database were followed for survival until December 31, 2021. Muscle mass was measured using dual X-ray absorptiometry, low muscle mass was defined as appendicular skeletal muscle mass index (ASMI) < 7.0 kg/m² in men or < 5.5 kg/m² in women. The relationship between ASMI and mortality was analyzed using weighted Cox regression.
resultsThe study included 892 participants (weighted mean [SE] age 52.22 [0.59] years, 57.36% female). During a median (SE) follow-up of 11.44 (0.33) years, 291 deaths (32.62%) were recorded, of which 197 (28.23%) were attributed to cardiovascular disease. In fully adjusted models, a 1 kg/m²increase in ASMI was associated with decreased all-cause and cardiovascular mortality risk by 34% (HR = 0.66, 95% CI 0.50-0.86) and 40% (HR = 0.60, 95% CI 0.38-0.93), respectively. When ASMI stratified, RA with low muscle mass had a 1.42-fold higher risk of all-cause mortality (HR = 1.42, 95% CI 1.01-2.00) and a 2.58-fold higher risk of cardiovascular mortality (HR = 2.58, 95% CI 1.18-5.62) than those with normal muscle mass. Restricted cubic spline analysis showed a nonlinear association between ASMI and cardiovascular (P
conclusionsMuscle loss in RA patients is linked to higher mortality risk, underscoring the need to recognize its harmful effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.